chrm1
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">chrm1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CHRM1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>chrm1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=CHRM1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
CHRM1 (Cholinergic Receptor Muscarinic 1) encodes the M1 muscarinic acetylcholine receptor, the most extensively studied muscarinic receptor subtype in the context of Alzheimer's disease and cognitive function. As a Gq protein-coupled receptor, CHRM1 activates phospholipase C signaling pathways that lead to increased intracellular calcium, activation of protein kinase C, and downstream effects on synaptic plasticity, gene expression, and neuronal survival.[@mg2022]
The M1 receptor is the predominant muscarinic receptor in the mammalian brain, with particularly high expression in regions critical for learning and memory, including the hippocampus and cortex. This distribution, combined with its role in activating signaling pathways important for cognition, has made CHRM1 a primary target for drug development in Alzheimer's disease.
Despite decades of research and numerous clinical trials, M1-selective agonists have not yet achieved clinical success due to challenges including poor selectivity, side effects, and lack of sustained efficacy.[@ssm2025] However, advances in structure-based drug design and the development of positive allosteric modulators have renewed interest in CHRM1 as a therapeutic target.
This comprehensive review examines the structure, function, signaling mechanisms, expression patterns, and disease associations of CHRM1, with emphasis on its role in Alzheimer's disease pathogenesis and the ongoing efforts to develop effective M1-targeted therapeutics.
Gene and Protein Structure
Gene Organization
The CHRM1 gene (Gene ID: 1128) is located on chromosome 11q12.3 and encodes a 460-amino acid protein. Unlike some GPCRs that undergo extensive alternative splicing, CHRM1 is encoded by a single-exon gene, simplifying its expression regulation. The gene promoter contains multiple transcription factor binding sites, including elements responsive to neuronal activity and cellular stress.
Protein Architecture
The M1 muscarinic receptor exemplifies the canonical seven-transmembrane GPCR fold:
Extracellular Domains:
- N-terminal domain (1-50 amino acids): Contains potential N-linked glycosylation sites
- Extracellular loops 1-3: Form the outer entrance to the ligand-binding pocket
Transmembrane Domain:
- Seven alpha-helices (TM1-TM7): Form the hydrophobic core
- Conserved sequence motifs: Maintain structural integrity and enable ligand binding
Intracellular Domains:
- Intracellular loops 1-3: Couple to G proteins and contain regulatory phosphorylation sites
- C-terminal tail: Contains serine/threonine residues for phosphorylation and β-arrestin recruitment
Ligand Binding Sites
The orthosteric binding site is located deep within the transmembrane domain, formed by residues from multiple helices. The binding pocket accommodates acetylcholine and various pharmacological ligands. Key features include:
- Conserved aspartic acid in TM3 (Asp105) as a critical anchor for agonist binding
- Multiple aromatic residues that form hydrophobic interactions with ligands
- A hydrophobic pocket that accommodates the tropine moiety of antagonist
Structural Dynamics
Crystal structures of M1 and related muscarinic receptors reveal:
- Conformational changes upon agonist binding that propagate to intracellular domains
- Multiple ligand-binding modes for agonists versus antagonists
- Allosteric sites that can be targeted for more selective modulation
Signaling Pathways
Primary Gq/11 Signaling
CHRM1 predominantly couples to Gq/11 proteins, leading to activation of phospholipase Cβ (PLCβ):
Phospholipase Cβ Activation: Gq activates PLCβ, cleaving phosphatidylinositol 4,5-bisphosphate (PIP2) into:
- Inositol 1,4,5-trisphosphate (IP3): Triggers calcium release from endoplasmic reticulum stores
- Diacylglycerol (DAG): Activates protein kinase C (PKC)
Calcium Signaling: IP3-mediated calcium release activates:
- Calmodulin-dependent protein kinases
- Calcineurin (PP2B)
- Various calcium-dependent transcription factors
Protein Kinase C Activation: DAG and calcium co-activate PKC isoforms, leading to:
- Phosphorylation of ion channels and receptors
- Modulation of synaptic vesicle trafficking
- Regulation of gene expression
Secondary Signaling Pathways
Beyond PLC, CHRM1 activates additional signaling cascades:
MAPK Pathways: Activation of ERK1/2, JNK, and p38 MAP kinases
PI3K/Akt Pathway: Pro-survival signaling through Akt activation
cAMP Modulation: Gq can cross-talk to increase cAMP through PLC-mediated mechanismsβ-Arrestin Signaling
Like other GPCRs, CHRM1 can signal through β-arrestin adapters:
- Receptor internalization
- ERK activation
- Akt signaling
Expression Patterns
Brain Region Distribution
CHRM1 exhibits widespread expression throughout the central nervous system:
Hippocampus: Highest expression in CA1, CA3, and dentate gyrus regions
- Essential for synaptic plasticity and memory formation
- Critical for spatial memory and contextual learning
Cortex: High expression in all cortical regions
- Prefrontal cortex: Executive function and working memory
- Entorhinal cortex: Gateway for hippocampal inputs
- Auditory, visual, and somatosensory cortices
Striatum: Moderate expression in striatal medium spiny neurons
- Modulation of motor control circuits
Thalamus: Expression in various thalamic nuclei
- Sensory processing and relay
Basal Forebrain: Expression on cholinergic neurons themselves
Cellular Localization
CHRM1 is expressed in:
- Pyramidal neurons: Principal excitatory neurons in cortex and hippocampus
- Interneurons: Various GABAergic inhibitory neurons
- Astrocytes: Modulation of astrocytic calcium signaling
- Microglia: Limited expression, modulation of inflammatory responses
Physiological Functions
Learning and Memory
M1 receptors are essential for multiple aspects of learning and memory:
Synaptic Plasticity: M1 activation is required for:
- Long-term potentiation (LTP) in hippocampal CA1
- Long-term depression (LTD) in cortex and hippocampus
- Novel object recognition memory
Memory Consolidation: M1 signaling during memory encoding enables:
- Transfer of information from short-term to long-term storage
- Contextual memory formation
- Emotional memory processing
Working Memory: M1 receptors in prefrontal cortex support:
- Maintenance of information online
- Rule learning and flexibility
Neuronal Excitability
CHRM1 modulates neuronal excitability through:
Hyperpolarization: Activation of calcium-activated potassium channels
Excitability Modulation: Regulation of sodium and potassium channel function
Dendritic Integration: Effects on dendritic spine morphology and functionAmyloid Processing
M1 receptor activation influences amyloid precursor protein (APP) processing:
Non-Amyloidogenic Processing: M1 activation promotes α-secretase activity
- Increases production of soluble APPα (sAPPα)
- Reduces amyloid-β generation
α-Secretase Regulation: M1 signaling activates ADAM10, the primary α-secretase
- TACE/ADAM17 may also be involved
- Provides neuroprotective sAPPα fragment
Tau Phosphorylation
M1 signaling intersects with tau pathology:
GSK-3β Modulation: M1 can regulate GSK-3β activity
- Effects on tau phosphorylation sites
- Potential for both protective and pathological outcomes
Kinase-Phosphatase Balance: M1 modulates balance between tau kinases and phosphatasesNeuroprotection
M1 receptor activation can provide neuroprotective effects:
Anti-apoptotic Signaling: Akt and ERK pathways promote neuronal survival
Metabolic Support: Enhanced glucose metabolism and mitochondrial function
Anti-inflammatory Effects: Modulation of microglial activationDisease Associations
Alzheimer's Disease
CHRM1 has been extensively studied in Alzheimer's disease due to:
Pathological Changes:
Receptor Loss: Post-mortem studies reveal M1 receptor binding is reduced in AD brains
- Loss correlates with cognitive decline
- Affects both cortical and hippocampal regions
Amyloid Interaction: Amyloid-β can:
- Directly bind to muscarinic receptors
- Impair M1 signaling through various mechanisms
- Contribute to synaptic dysfunction
Tau Pathology: Neurofibrillary tangles may disrupt M1 signaling complexes
- Loss of M1-coupled signaling contributes to plasticity deficits
Cholinergic Degeneration: Loss of basal forebrain neurons reduces acetylcholine tone
- Reduces M1 activation even when receptors remain
Therapeutic Implications:The M1 receptor has been a primary target for AD drug development:
Agonists: Direct M1 agonists tested in clinical trials
- Challenges: Lack of selectivity, side effects, limited efficacy
Positive Allosteric Modulators (PAMs): More selective approach
- Enhance endogenous acetylcholine signaling
- Potential for improved safety profile
Novel Strategies: Bitopic ligands, M1-selective compounds in developmentSchizophrenia
CHRM1 dysfunction has been implicated in schizophrenia:
Cognitive Deficits: M1 contributes to cognitive impairment in schizophrenia
Dysbindin Interaction: Genetic associations between CHRM1 and dysbindin may affect signaling
Therapeutic Potential: M1 modulators may improve cognitive symptomsOther Conditions
Parkinson's Disease: M1 may contribute to cognitive symptoms
Drug Addiction: M1 signaling in reward circuits
Epilepsy: Modulation of neuronal excitabilityClinical Development
Historical Perspective
M1 agonist development has a long history:
First Generation: Non-selective muscarinic agonists
- Limited by peripheral side effects
- Poor brain penetration
Second Generation: More M1-selective compounds
- Improved selectivity
- Still faced efficacy and safety challenges
Current Approaches: Structure-guided design and PAMsCurrent Status
Several M1-targeted approaches are in development:
M1 Agonists: BT-1, other compounds in trials
M1 PAMs: Various compounds in preclinical/early clinical development
M1-Selective Bitopic Ligands: Dual-targeting approachChallenges
Selectivity: Achieving true M1 selectivity over other muscarinic subtypes
Efficacy: Demonstrating meaningful cognitive improvement
Safety: Managing cholinergic side effects
Biomarkers: Patient selection and treatment response monitoringFuture Directions
Combination Therapies: M1 modulators with other mechanisms
Disease Modification: Effects beyond symptom improvement
Personalized Medicine: Biomarker-guided treatmentInteraction with Other Proteins and Pathways
G Protein Interactions
CHRM1 primarily couples to:
- Gq/11 family proteins (GNAQ, GNA14, GNA15)
- Can also engage Gβγ subunits
- Variations in coupling efficiency across brain regions
Scaffold Proteins
M1 receptors interact with various scaffolding proteins:
- GRK phosphorylation sites
- PDZ domain proteins
- Kinase complexes
Cross-Talk
CHRM1 signaling intersects with:
Dopaminergic Signaling: M1 can modulate dopamine receptor function
Glutamatergic Signaling: Effects on NMDA and AMPA receptor function
Amyloid Processing: α-secretase activation
Tau Kinases: GSK-3β and other tau-modifying enzymesAnimal Models
Knockout Studies
CHRM1 knockout mice exhibit:
- Impaired learning and memory
- Reduced LTP
- Altered responses to muscarinic drugs
Transgenic Models
Various models have been used to study:
- M1 overexpression effects
- Conditional knockout systems
- Disease model interactions
Molecular Mechanisms in AD
Synaptic Dysfunction
M1 signaling is critical for synaptic plasticity, and its disruption contributes to AD:
LTP Impairment: M1 is required for activity-dependent LTP
Spine Loss: M1 signaling maintains dendritic spine density
Translation Control: M1 regulates protein synthesis at synapsesNeuronal Survival
M1 activation promotes neuronal survival through:
Akt Pathway: Pro-survival signaling
ERK Pathway: Activity-dependent neuroprotection
Metabolic Support: Enhanced mitochondrial functionAmyloid Tolerance
M1 signaling may provide resilience to amyloid pathology:
Enhanced Clearance: Potential effects on Aβ degradation
Synaptic Protection: Maintaining plasticity despite pathology
Compensatory Upregulation: Possible adaptive responsesPharmacological Considerations
Agonist Pharmacology
Muscarinic agonists vary in their M1 selectivity:
Muscarine: Non-selective muscarinic agonist
Oxotremorine: Mixed M1/M2 agonist
Bethanechol: M1-preferring, limited brain penetrationAntagonist Properties
M1 antagonists include:
Atropine: Non-selective antagonist
Pirenzepine: M1-selective antagonist (GI uses)
Telenzepine: M1-selective, higher potencyAllosteric Modulation
Allosteric sites offer new therapeutic opportunities:
Positive Allosteric Modulators: Enhance agonist efficacy
Negative Allosteric Modulators: Reduce excessive signaling
Allosteric Agonists: Activate receptor through allosteric siteFuture Perspectives
Research Priorities
Structural Studies: Continue structure-based drug design
Signal Bias: Understand G protein vs β-arrestin bias for optimal outcomes
Biomarkers: Develop M1-related biomarkers for patient selectionClinical Outlook
The M1 receptor remains a compelling target for:
- Symptomatic treatment of cognitive impairment
- Potential disease-modifying effects
- Combination approaches with other mechanisms
As understanding of M1 biology advances and drug development tools improve, the potential for effective M1-targeted therapies for Alzheimer's disease continues to evolve.
M1 Receptor in Neuroinflammation
Emerging evidence suggests that CHRM1 plays a role in neuroinflammatory processes relevant to neurodegenerative diseases:
Microglial Activation
M1 receptors are expressed on microglia and influence inflammatory responses:
- M1 activation can enhance pro-inflammatory cytokine production
- Modulates microglial phagocytosis
- Affects antigen presentation and immune surveillance
Astrocyte Function
Astrocytic M1 receptors regulate:
- Calcium signaling and glutamate uptake
- Cytokine and chemokine release
- Metabolic support for neurons
Therapeutic Implications
Targeting M1 in neuroinflammation may provide benefits:
- Reducing excitotoxicity through astrocyte modulation
- Modulating cytokine-mediated neuronal damage
- Potential for disease modification
M1 and Circadian Rhythm
Recent research has revealed connections between M1 receptor signaling and circadian regulation:
Hippocampal Circadian Function
M1 signaling exhibits circadian variation:
- Daily rhythms in M1 receptor expression
- Effects on memory performance at different times of day
- Interactions with clock gene expression
Therapeutic Implications
Circadian considerations for M1-targeted therapy:
- Timing of drug administration
- Circadian dysfunction in AD
- Chronotherapeutic approaches
Genetic Considerations
CHRM1 Polymorphisms
Genetic variations in CHRM1 have been studied:
- Association with cognitive performance
- Response to cholinergic medications
- Risk for certain neurological conditions
Gene Expression Regulation
CHRM1 expression is regulated by:
- Neuronal activity
- Epigenetic modifications
- Transcription factors including CREB
M1 in Blood-Brain Barrier Function
M1 receptors influence blood-brain barrier (BBB) integrity:
Endothelial Function
M1 signaling affects:
- Tight junction protein expression
- Transport across the BBB
- Neuroimmune signaling at the BBB
Implications for Drug Delivery
Understanding BBB penetration is critical for:
- CNS drug development
- Targeting strategies
- Combination therapies
External Links
- [NCBI Gene - CHRM1](https://www.ncbi.nlm.nih.gov/gene/1128) - Gene database entry
- [OMIM - CHRM1](https://www.omim.org/entry/103960) - Online Mendelian Inheritance in Man
- [UniProt - CHRM1](https://www.uniprot.org/uniprotkb/P11229/entry) - Protein sequence data
- [Ensembl - CHRM1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168539) - Genomic resources
- [Allen Brain Atlas - CHRM1](https://brain-map.org/) - Gene expression data
- [PubMed - CHRM1](https://pubmed.ncbi.nlm.nih.gov/?term=CHRM1+muscarinic+receptor+Alzheimer) - Literature search
References
[Muscarinic acetylcholine receptors in the central nervous system (2020)](https://doi.org/10.1016/j.neuroscience.2020.01.001)
[Muscarinic acetylcholine receptor structure and ligand binding (2021)](https://doi.org/10.1016/j.tips.2021.03.003)
[Muscarinic M1 receptor as a therapeutic target for Alzheimer's disease (2021)](https://doi.org/10.1016/j.neuropharm.2021.108497)
[M1 muscarinic receptor signaling in neuronal function and survival (2022)](https://doi.org/10.1111/bph.15845)
[M1 muscarinic receptor agonists for Alzheimer's disease clinical trials (2020)](https://doi.org/10.1002/alz.042438)
[The cholinergic hypothesis of Alzheimer's disease: 40 years of progress (2022)](https://doi.org/10.1016/j.neurobiolaging.2021.11.015)
[M1 muscarinic receptors in hippocampal synaptic plasticity and memory (2021)](https://doi.org/10.1016/j.neuropharm.2021.108233)
[Muscarinic receptor modulation of amyloid precursor protein processing (2020)](https://doi.org/10.1111/bnc.14789)
[Muscarinic receptor signaling and tau pathology in Alzheimer's disease (2022)](https://doi.org/10.3233/JAD-215423)
[M1 muscarinic receptor positive allosteric modulators for cognitive enhancement (2023)](https://doi.org/10.3390/brainsci13020367)
[Gq protein-coupled receptor signaling in neural development and disease (2021)](https://doi.org/10.1016/j.tips.2021.06.004)
[Clinical development of muscarinic receptor agonists for neurodegeneration (2023)](https://doi.org/10.1016/j.drudis.2022.12.010)
[M1 muscarinic receptor agonists in Alzheimer's disease: translational challenges (2021)](https://doi.org/10.1111/bph.15421)
[Structure of the M1 muscarinic receptor and basis for drug design (2020)](https://doi.org/10.1016/j.bioact.2020.04.006)
[Muscarinic receptor subtypes in learning and memory (2021)](https://doi.org/10.1016/j.nlm.2021.03.007)Pathway Diagram
The following diagram shows the key molecular relationships involving chrm1 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
See Also
- [POLE — DNA Polymerase Epsilon](/wiki/genes-pole) — regulates
- [VTA Dopamine Neurons in Schizophrenia](/wiki/cell-types-vta-dopamine-schizophrenia) — regulates
- [Astrocytes in Neurodegeneration](/wiki/cell-types-astrocytes-neurodegeneration) — expressed_in
- [Microglia Depletion and Repopulation Therapy](/wiki/therapeutics-microglia-depletion-repopulation) — expressed_in
- [Neuroinflammation and Microglia Pathway in Alzheimer's Disease](/wiki/mechanisms-ad-neuroinflammation-microglia-pathway) — activates
- [Neurons in Dentatorubral-Pallidoluysian Atrophy](/wiki/cell-types-dentatorubral-pallidoluysian-atrophy-neurons) — expressed_in
- [Brain-Derived Neurotrophic Factor (BDNF)](/wiki/proteins-bdnf) — inhibits
- [Brain-Derived Neurotrophic Factor (BDNF)](/wiki/proteins-bdnf) — activates
Pathway Diagram
The following diagram shows the key molecular relationships involving chrm1 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)